DEA cough/cold ingredient seizure upheld
This article was originally published in The Tan Sheet
Executive Summary
The U.S. Court of Appeals for the District of Columbia Circuit affirms the dismissal of a complaint filed by Malladi Drugs & Pharmaceuticals against the Drug Enforcement Administration seeking the return of $1.42 million worth of seized ephedrine and pseudoephedrine. The court's Jan. 23 ruling says India-based Malladi, which manufactures OTC and Rx pharmaceutical ingredients in the U.S. through subsidiary Novus Fine Chemicals, "failed to exhaust its administrative remedies" with DEA immediately following the seizure, such as filing a claim for the property. DEA agents seized the chemicals from Malladi's New Jersey facility in 2005 after discovering the company's file room was not sufficiently organized to reconcile documentation and inventory
You may also be interested in...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: